CDK2

CDK2
Name	Cyclin-dependent kinase 2
Organism	Homo sapiens
Uniprot	P24941
Family	Cyclin-dependent kinase family

CDK2 CDK2 is a serine/threonine protein kinase that coordinates cell cycle progression in eukaryotic cells. Discovered through biochemical purification studies linked to cell division, CDK2 interacts with regulatory cyclins and integrates signals from growth factor receptors and DNA damage sensors. Its activity is central to transitions during the G1/S and S phases and is studied across model organisms, cancer biology, and drug discovery programs.

Introduction

CDK2 was identified during efforts involving researchers at institutions such as University of Cambridge, Harvard Medical School, Cold Spring Harbor Laboratory, Max Planck Society, and The Scripps Research Institute that traced kinase activities controlling the cell cycle. Early characterizations connected CDK2 to cyclins first described in studies involving Xenopus laevis oocyte maturation and later to mammalian mitotic control in work led by groups at Massachusetts Institute of Technology and University of California, San Francisco. CDK2 occupies a central node in signaling networks that include inputs from receptor tyrosine kinases like Epidermal growth factor receptor and stress-response pathways such as those mediated by ATM and ATR kinases.

Structure and Regulation

The CDK2 catalytic core adopts the conserved bilobed kinase fold first elucidated in structural studies at facilities including European Molecular Biology Laboratory and Stanford Synchrotron Radiation Lightsource. Activation requires cyclin binding (notably cyclin A and cyclin E) and phosphorylation of the activation loop by CDK-activating kinase complexes characterized by researchers at Institute Pasteur and EMBL. Negative regulation occurs through association with CDK inhibitors from the CIP/KIP family and the INK4 family, mechanisms explored in labs at University of Oxford and Johns Hopkins University. Ubiquitin-mediated proteolysis of cyclins by E3 ligases such as the Anaphase-promoting complex and SCF complexes, described by groups at Max Planck Institute of Biochemistry and Columbia University, provides temporal control. High-resolution crystallography and cryo-EM work at Brookhaven National Laboratory and Rutherford Appleton Laboratory refined models of inhibitor-bound and substrate-bound states.

Cellular Functions and Pathways

CDK2-cyclin complexes phosphorylate substrates involved in DNA replication, origin firing, and replication fork progression, topics advanced by teams at Cold Spring Harbor Laboratory and European Molecular Biology Laboratory. CDK2 targets include factors implicated in origin licensing such as CDC6 and components of the pre-replication complex studied in collaborations with National Institutes of Health researchers. Integration with checkpoint control occurs via interactions with p53 pathway constituents uncovered in studies at University of Pennsylvania and Dana-Farber Cancer Institute. CDK2 signaling interfaces with chromatin regulators examined at Max Planck Institute for Molecular Genetics and transcriptional programs mapped by consortia including ENCODE. Cross-talk between CDK2 activity and mitogenic cascades involving RAS, PI3K, and MAPK pathways has been described by multiple cancer biology groups.

Role in Disease and Cancer

Aberrant CDK2 activity is implicated in oncogenesis through dysregulation of cyclins (for example, cyclin E amplifications) documented in clinical cohorts analyzed at Memorial Sloan Kettering Cancer Center and Mayo Clinic. Tumor types with altered CDK2 axis include breast cancer characterized by studies at MD Anderson Cancer Center, ovarian cancer cohorts from Royal Marsden Hospital, and lung cancers profiled by teams at Fred Hutchinson Cancer Research Center. Loss of checkpoint control tied to defective CDK2 regulation cooperates with mutations in tumor suppressors such as RB1 and TP53, a relationship dissected in genetic studies at Broad Institute and Sanger Institute. Beyond oncology, CDK2 dysregulation has been explored in contexts of neurodegeneration investigated by researchers at Karolinska Institute and in viral replication cycles studied at Pasteur Institute virology groups.

Clinical Significance and Therapeutics

CDK2 has been a target for small-molecule inhibitor development pursued by pharmaceutical groups at Pfizer, Novartis, AstraZeneca, and biotech companies like Cyclacel Pharmaceuticals. Clinical trials coordinated through networks such as National Cancer Institute and European Medicines Agency explored selective and pan-CDK inhibitors, with outcomes informing combination strategies with endocrine therapies at Royal Marsden and targeted agents from Genentech. Resistance mechanisms involving compensatory activation of CDK4/6 or alterations in cell-cycle regulators were characterized in translational studies at University College London and Vanderbilt University Medical Center. Biomarker efforts linking cyclin E overexpression and RB pathway status to treatment response involve clinical genomics centers at Memorial Sloan Kettering and Dana-Farber Cancer Institute.

Experimental Methods and Models

Functional studies of CDK2 leverage genetic approaches including CRISPR-Cas9 knockouts optimized at Broad Institute and RNAi screens pioneered at Whitehead Institute. Biochemical assays using recombinant proteins originate from structural biology cores at European Molecular Biology Laboratory and Scripps Research Institute, while live-cell imaging of cell-cycle dynamics uses microscopy platforms developed at Max Planck Institute for Cell Biology and Genetics and Janelia Research Campus. Model organisms such as Saccharomyces cerevisiae, Drosophila melanogaster, Mus musculus, and Xenopus laevis provide conserved context for functional dissection in labs at Cold Spring Harbor Laboratory, Howard Hughes Medical Institute, and university research centers worldwide. Large-scale omics resources from consortia like Cancer Genome Atlas and International Cancer Genome Consortium support translational analyses linking CDK2 pathway alterations to clinical phenotypes.

Category:Cell cycle proteins